- Home
- ELMD vs VCRE Comparison
ELMD vs VCRE Comparison
Compare ELMD & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ELMD | VCRE |
|---|---|---|
| Founded | 1992 | N/A |
| Country | United States | Sweden |
| Employees | N/A | 40 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 326.9M | 332.9M |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | ELMD | VCRE |
|---|---|---|
| Price | $39.45 | $12.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $36.00 | N/A |
| AVG Volume (30 Days) | ★ 48.1K | 4.5K |
| Earning Date | 05-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.55 | N/A |
| EPS | ★ 0.91 | N/A |
| Revenue | ★ $54,716,000.00 | N/A |
| Revenue This Year | $15.59 | N/A |
| Revenue Next Year | $11.51 | N/A |
| P/E Ratio | $43.96 | ★ N/A |
| Revenue Growth | ★ 13.83 | N/A |
| 52 Week Low | $19.93 | $10.50 |
| 52 Week High | $47.40 | $13.00 |
Technical Indicators
Market Signals| Indicator | ELMD | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 44.85 | 46.02 |
| Support Level | $35.61 | $10.74 |
| Resistance Level | $43.61 | $12.93 |
| Average True Range (ATR) | 1.41 | 0.45 |
| MACD | -0.22 | 0.08 |
| Stochastic Oscillator | 19.53 | 60.69 |
Price Performance
Historical ComparisonAbout ELMD Electromed Inc.
Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.
About VCRE Vicore Pharma Holding AB American Depositary Shares
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.